EUVIMEDEUVIMED entdecken
Crossref

Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma

Amy Y. Huang, Kelly P. Burke, Marc C. Glettig, Ryan Porter, Peter Fatouros, Jonathan M. Li, Lynn Meiger, Valeria Rosado, Shuyun Xu, Jiekun Yang, Emily Robitschek, Natalie Vokes und 17 weitere

Science Advances · 20.11.2026 · 12 (47)

DOI: 10.1126/sciadv.aed0035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 20.11.2026. Verfasst von Amy Y. Huang und 28 weiteren Autor:innen. Die Arbeit nennt 88 Literaturangaben. Gefördert von: National Institutes of Health, American Association for Cancer Research, National Cancer Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While immune-checkpoint blockade (ICB) has revolutionized treatment of metastatic melanoma, the identification of robust biomarkers to predict the relative efficacy of single versus combination ICB has been challenging. We performed a meta-analysis of eight cohorts of patients treated with anti–PD-1 ( n = 290), anti–CTLA-4 ( n = 175), and combination anti–PD-1/anti–CTLA-4 ( n = 51) with pretreatment tumor sequencing and clinical annotations. Surprisingly, the increased response rate to combination anti–PD-1/anti–CTLA-4 compared to anti–PD-1 monotherapy was observed only in highly immune infiltrated tumors, and not in immune-low tumors. Stratifying tumors by high or low frequency of immune cells also distinguished context-dependent programs of primary resistance to single and combination ICB. Notably, hypoxia-related pathways were enriched in nonresponders to anti–PD-1 ICB in immune-high, but not immune-low, tumors. Using an independent cohort of patients with scRNA-seq data, we observed that correlates of hypoxia were associated with increased stromal tumor receptor-ligand interactions. As proof of concept, selective inhibition of HIF-2α, a component of the hypoxia pathway and highly expressed in endothelial cells and fibroblasts, in combination with anti–PD-1, controlled tumor growth in mouse models of highly immune-infiltrated tumors but not poorly immune-infiltrated tumors. Our work demonstrates how stratification by tumor immune characteristics and clinical features can lead to the rational discovery of novel therapeutic targets.

Förderung

  • National Institutes of Health
  • American Association for Cancer Research
  • National Cancer Institute
  • Doris Duke Charitable Foundation
  • American-Italian Cancer Foundation
  • Barr Foundation
  • Society for Immunotherapy of Cancer
  • Adelson Medical Research Foundation

Zitieren

APA

Huang, A. Y., Burke, K. P., Glettig, M. C., Porter, R., Fatouros, P., Li, J. M., Meiger, L., Rosado, V., Xu, S., Yang, J., Robitschek, E., Vokes, N., Ricker, C., Tarantino, G., Chen, J., Aprati, T. J., He, Y., Wang, C., Fu, D., …, & Liu, D. (2026). Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma. Science Advances, 12(47). https://doi.org/10.1126/sciadv.aed0035

Vancouver

Huang AY, Burke KP, Glettig MC, Porter R, Fatouros P, Li JM, et al. Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma. Science Advances. 2026;12(47). doi:10.1126/sciadv.aed0035

BibTeX
@article{Huang2026,
  author = {Huang, Amy Y. and Burke, Kelly P. and Glettig, Marc C. and Porter, Ryan and Fatouros, Peter and Li, Jonathan M. and Meiger, Lynn and Rosado, Valeria and Xu, Shuyun and Yang, Jiekun and Robitschek, Emily and Vokes, Natalie and Ricker, Cora and Tarantino, Giuseppe and Chen, Jiajia and Aprati, Tyler J. and He, Yiwen and Wang, Cassia and Fu, Doris and Ho, Li-Lun and Galani, Kyriakitsa and Freeman, Gordon J. and Buchbinder, Elizabeth I. and Hodi, F. Stephen and Lian, Christine G. and Kellis, Manolis and Boland, Genevieve M. and Sharpe, Arlene H. and Liu, David},
  title = {Immune infiltrate predicts response to αPD1/αCTLA4 but not αPD1 and distinguishes programs of primary resistance in metastatic melanoma},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {47},
  doi = {10.1126/sciadv.aed0035}
}
Kostenlos starten →